Patents by Inventor Alan J. Korman

Alan J. Korman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190276539
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Applicant: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. Leblanc
  • Publication number: 20190276538
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Applicant: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. Leblanc
  • Publication number: 20190248893
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Application
    Filed: July 13, 2017
    Publication date: August 15, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Y. HUANG, Guodong CHEN, Michelle KUHNE, Hong-An TRUONG
  • Patent number: 10344089
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 9, 2019
    Assignee: E.R. Squibb & Sons, L.L.C.
    Inventors: Kent B. Thudium, Mark J. Selby, Kyra D. Zens, Mark Yamanaka, Alan J. Korman, Heidi N. LeBlanc
  • Publication number: 20190175705
    Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.
    Type: Application
    Filed: February 21, 2019
    Publication date: June 13, 2019
    Inventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
  • Publication number: 20190119381
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Application
    Filed: October 31, 2018
    Publication date: April 25, 2019
    Inventors: Jennifer Marie MATARAZA, Andrea Van ELSAS, Alan J. KORMAN, Edward L. HALK, Kent B. THUDIUM, Mark J. SELBY, Timothy W. SPROUL, Heidi N. LEBLANC
  • Publication number: 20190119384
    Abstract: The presently subject matter provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: December 26, 2018
    Publication date: April 25, 2019
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Patent number: 10251945
    Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 9, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
  • Publication number: 20190076515
    Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.
    Type: Application
    Filed: November 21, 2018
    Publication date: March 14, 2019
    Inventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
  • Publication number: 20190062456
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 28, 2019
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, JR., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
  • Publication number: 20190055320
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Application
    Filed: August 27, 2018
    Publication date: February 21, 2019
    Inventors: Nils LONBERG, Alan J. KORMAN, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Ming LEI, Emanuela SEGA, Angela GOODENOUGH, Maria JURE-KUNKEL, Guodong CHEN, John S. SACK, Richard Y. HUANG, Martin J. CORBETT, Joseph E. MYERS, JR., Liang SCHWEIZER, Sandra V. HATCHER, Haichun HUANG, Pingping ZHANG
  • Patent number: 10196445
    Abstract: The present invention provides anti-CTLA-4 antibodies having enhanced ADCC activity, and their use in treating cancer. In one embodiment, the anti-CTLA-4 antibody is ipilimumab, and ADCC activity is enhanced by introducing G236A, S239D, A330L and I332E mutations (“GASDALIE”) into the Fc region of the heavy chain constant domain.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: February 5, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Engelhardt, Alan J. Korman, Mark J. Selby
  • Publication number: 20190031763
    Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Inventors: MICHELLE R. KUHNE, Peter Brams, Dawn M. Tanamachi, Alan J. Korman, Josephine M. Cardarelli
  • Patent number: 10167343
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: January 1, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
  • Patent number: 10155813
    Abstract: The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 18, 2018
    Assignee: E. R. Squibb & Sons, L.L.C.
    Inventors: Jennifer Marie Mataraza, Andrea Van Elsas, Alan J. Korman, Edward L. Halk, Kent B. Thudium, Mark J. Selby, Timothy W. Sproul, Heidi N. Leblanc
  • Publication number: 20180339042
    Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
    Type: Application
    Filed: November 17, 2016
    Publication date: November 29, 2018
    Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan Chien-Szu WONG, Huiming LI, Bryan C. BARNHART, Aaron P. YAMNIUK, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
  • Publication number: 20180333502
    Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
    Type: Application
    Filed: November 19, 2015
    Publication date: November 22, 2018
    Inventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
  • Publication number: 20180312553
    Abstract: The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method and its use in treating a subject afflicted with a cancer or a disease caused by an infectious agent.
    Type: Application
    Filed: February 13, 2018
    Publication date: November 1, 2018
    Inventors: John J. ENGELHARDT, Alan J. KORMAN, Michael QUIGLEY, Mark J. SELBY, Changyu WANG
  • Publication number: 20180298097
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Application
    Filed: June 25, 2018
    Publication date: October 18, 2018
    Applicant: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F,. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Troung
  • Patent number: 10100129
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: October 16, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang